Skip to main content
. 2017 Sep 12;2017:4934608. doi: 10.1155/2017/4934608

Figure 2.

Figure 2

Classification of the high-risk breast cancer subtypes. PITX2 DNA methylation status can serve as a significant predictive biomarker for anthracycline-based chemotherapy in the two major high-risk breast cancer subtypes [44, 66].